find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
298
Clinical Trials
Leukemia
Phase I/II
Active
nct/study# NCT02152956 / CP-MGD006-01
A Phase 1/2, First-in-Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic Syndrome
Learn More
Leukemia
Phase I/II
Active
nct/study# NA / KO-MEN-001
KO-539 Menin-KMT2A (MLL) inhibitor Phase ½ R/R AML with NPM1 Mutation) A Phase 1/2A First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemi
Learn More
Leukemia
Phase I/II
Active
nct/study# NA / GSK3326595
A Phase I/II Study To Investigate The Safety And Clinical Activity Of GSK3326595 And Other Agents In Subjects With Myelodyplastic Syndrome And Acute Myeloid Leukaemia
Learn More
Leukemia
Phase III
Active
nct/study# NA / GS-US-546-5857
Phase 3 Study To Evaluate The Safety And Efficacy Of Magrolimab In Combination With Azacitidine Versus Physician’s Choice Of Venetoclax In Combination With Azacitidine Or Intensive Chemotherapy In Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia (ENHANCE-2)
Learn More
Leukemia
Phase I/II
Active
nct/study# NA / APTEVO
Phase 1-2 Study Of A Bispecific CD3xCD123 Antibody In Acute Myeloid Leukemia Patients
Learn More
Lung Cancer Clinical Trials
II
Accepting Patients
nct/study# NCT04623775 / CA224-104
A Study Of Relatlimab Plus Nivolumab In Combination With Chemotherapy Vs. Nivolumab In Combination With Chemotherapy In Participants With Stage IV Or Recurrent NSCLC
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.